Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer

AV Serritella, D Shevrin, EI Heath, JL Wade… - Clinical Cancer …, 2022 - AACR
Purpose: Although androgen deprivation therapy (ADT) and androgen receptor (AR)
signaling inhibitors are effective in metastatic prostate cancer, resistance occurs in most …
被引用次数：33 相关文章
[HTML] nih.gov

[HTML][HTML] Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer

AV Serritella, D Shevrin, EI Heath… - … cancer research: an …, 2022 - ncbi.nlm.nih.gov
Purpose: Although androgen deprivation therapy (ADT) and androgen receptor signaling
inhibitors (ARSI) are effective in metastatic prostate cancer (PC), resistance occurs in most …

Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer

AV Serritella, D Shevrin, EI Heath, JL Wade… - Clinical Cancer …, 2022 - AACR
Purpose: Although androgen deprivation therapy (ADT) and androgen receptor (AR)
signaling inhibitors are effective in metastatic prostate cancer, resistance occurs in most …

Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.

AV Serritella, D Shevrin, EI Heath, JL Wade… - … Cancer Research: an …, 2022 - europepmc.org
Purpose Although androgen deprivation therapy (ADT) and androgen receptor (AR)
signaling inhibitors are effective in metastatic prostate cancer, resistance occurs in most …

Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer

AV Serritella, D Shevrin, EI Heath… - Clinical Cancer …, 2022 - scholars.northwestern.edu
Purpose: Although androgen deprivation therapy (ADT) and androgen receptor (AR)
signaling inhibitors are effective in metastatic prostate cancer, resistance occurs in most …

Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer

AV Serritella, D Shevrin, EI Heath… - … : an official journal …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose Although androgen deprivation therapy (ADT) and androgen receptor (AR)
signaling inhibitors are effective in metastatic prostate cancer, resistance occurs in most …